Calcium sensitization in perfused beating guinea pig heart by a positive inotropic agent MCI-154

Y Abe1, R Ishisu, K Onishi

  • 1First Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan.

Insights

MCI-154, a novel positive inotropic agent, enhances cardiac contractility by increasing myofilament sensitivity to calcium (Ca++). This study reveals MCI-154

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Positive inotropic agents are crucial for managing heart failure.
  • Understanding the mechanisms of action for new agents like MCI-154 is vital.
  • Comparing MCI-154 with existing drugs (pimobendan, milrinone) provides clinical context.

Purpose of the Study:

  • To investigate the effects of MCI-154 on calcium (Ca++) transients, left ventricular (LV) function, and phosphodiesterase (PDE) III activity in guinea pig hearts.
  • To compare the efficacy and potency of MCI-154 with pimobendan and milrinone.

Main Methods:

  • Utilized Langendorff-perfused guinea pig hearts loaded with the fluorescent Ca++ probe indo-1.
  • Simultaneously measured LV pressure and Ca++ transients.
  • Assessed PDE III activity in isolated guinea pig LV tissues.

Main Results:

  • MCI-154 significantly increased LV developed pressure, +dP/dt, and -dP/dt, indicating potent positive inotropic effects.
  • MCI-154 demonstrated greater potency than pimobendan and milrinone in increasing contractility (EC50 values).
  • The drug increased Ca++ transients but to a lesser extent relative to contractility compared to other agents, suggesting Ca++ sensitization.

Conclusions:

  • MCI-154 exerts its positive inotropic effect primarily through calcium sensitization of cardiac myofilaments.
  • MCI-154 shows promise as a potent inotropic agent with a distinct mechanism compared to PDE III inhibitors.
  • Further research is warranted to explore the therapeutic potential of MCI-154 in cardiovascular conditions.